A comprehensive view of Clinical Trials. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.
CHMP recommends EU approval of Roche’s Alecensa monotherapy as the first adjuvant treatment for resected ALK-positive early-stage lung cancer; about half of people living with early-stage NSCLC experiencing disease recurrence or death following surgery
Published:
April 26, 2024
by F. Hoffmann-La Roche Ltd. (Roche)
|
Media Update: New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases
Published:
April 26, 2024
by Sanofi SA
|
'Tim-3 Antagonists For The Treatment And Diagnosis Of Cancers' in Patent Application Approval Process (USPTO 20240117044)
Published:
April 25, 2024
by NewsRx Pharma Business Daily
|
FDA accepts for priority review GSK’s application for an expanded indication of Jemperli dostarlimab-gxly plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer
Published:
April 24, 2024
by GSK Group (GlaxoSmithKline)
|
US Patent Issued to Regeneron Pharmaceuticals on April 23 for "Antigen binding molecule formats" (New York Inventors)
Published:
April 24, 2024
by U.S. Fed News
|
Ask us about our R&D/Patents market view